Compare HOVR & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ECOR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 81.0M |
| IPO Year | N/A | 2018 |
| Metric | HOVR | ECOR |
|---|---|---|
| Price | $1.57 | $5.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 997.1K | 93.5K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $1.16 | $4.16 |
| 52 Week High | $4.18 | $10.50 |
| Indicator | HOVR | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 34.54 | 35.06 |
| Support Level | $1.42 | $5.71 |
| Resistance Level | $1.91 | $7.17 |
| Average True Range (ATR) | 0.14 | 0.82 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 19.85 | 8.59 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.